Skip to main content

Advertisement

SpringerLink
Log in

Indications for neoadjuvant chemotherapy in older patients undergoing esophagectomy for esophageal cancer

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

To investigate the indications for neoadjuvant chemotherapy (NAC) in esophageal cancer patients aged 75 years or older.

Methods

We analyzed data, retrospectively, from 155 patients over 75 years old, who underwent esophagectomy for esophageal cancer between 2010 and 2020. Forty-one patients underwent upfront surgery (US group) and 114 were treated with NAC followed by surgery (NAC group). We compared the patient backgrounds and perioperative outcomes including prognosis, between the two groups.

Results

The NAC group patients were significantly younger and had significantly more advanced clinical stage disease than the US group patients. The incidence of postoperative complications was similar in the two groups. Patients with a good pathological response to NAC had a significantly better prognosis than those with a poor response and those in the US group. Among patients with a performance status (PS) of 0, the 5-year OS rate was 56.5% in the NAC group and 38.1% in the US group (HR = 0.63, 95% CI 0.35–1.12). Among those with a PS of 1–2, the 5-year OS rates were 28.1% and 57.1%, respectively (HR = 1.69, 95% CI 0.99–2.89; P = 0.037 for interaction).

Conclusions

NAC did not improve the postoperative prognosis of older esophageal cancer patients with a PS of 1 or higher.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Eyck BM, van Lanschot JJB, Hulshof M, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39:1995–2004.

    Article  CAS  PubMed  Google Scholar 

  2. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.

    Article  PubMed  Google Scholar 

  3. Sugimura K, Yamasaki M, Yasuda T, Yano M, Hirao M, Fujitani K, et al. Long-term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5-fluorouracil vs docetaxel, cisplatin, and 5-fluorouracil followed by surgery for esophageal cancer (OGSG1003). Ann Gastroenterol Surg. 2021;5:75–82.

    Article  PubMed  Google Scholar 

  4. Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2. Esophagus. 2023;20:373–89.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20:343–72.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Watanabe M, Toh Y, Ishihara R, Kono K, Matsubara H, Murakami K, et al. Comprehensive registry of esophageal cancer in Japan, 2014. Esophagus. 2022;19:1–26.

    Article  PubMed  Google Scholar 

  7. Yamashita K, Watanabe M, Mine S, Fukudome I, Okamura A, Yuda M, et al. The impact of the Charlson comorbidity index on the prognosis of esophageal cancer patients who underwent esophagectomy with curative intent. Surg Today. 2018;48:632–9.

    Article  PubMed  Google Scholar 

  8. Oguma J, Ozawa S, Ishiyama K, Daiko H. Clinical significance of sarcopenic dysphagia for patients with esophageal cancer undergoing esophagectomy: A review. Ann Gastroenterol Surg. 2022;6:738–45.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol. 2003;21:4592–6.

    Article  PubMed  Google Scholar 

  10. Yamasaki M, Yasuda T, Yano M, Hirao M, Kobayashi K, Fujitani K, et al. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Ann Oncol. 2017;28:116–20.

    Article  CAS  PubMed  Google Scholar 

  11. Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111:518–26.

    CAS  PubMed  Google Scholar 

  12. Japan ES. Japanese Classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.

    Article  Google Scholar 

  13. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22:881–6.

    Article  PubMed  Google Scholar 

  14. Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43:752–5.

    Article  PubMed  Google Scholar 

  15. Shiraishi O, Makino T, Yamasaki M, Tanaka K, Yamashita K, Ishida T, et al. Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial. Esophagus. 2021;18:825–34.

    Article  PubMed  Google Scholar 

  16. Miyata H, Tanaka K, Makino T, Yamasaki M, Miyazaki Y, Takahashi T, et al. The impact of pathological tumor regression and nodal status on survival and systemic disease in patients undergoing neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2018;25:2409–17.

    Article  PubMed  Google Scholar 

  17. Okamura A, Matsuda S, Mayanagi S, Kanamori J, Imamura Y, Irino T, et al. Clinical significance of pretherapeutic serum squamous cell carcinoma antigen level in patients with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2021;28:1209–16.

    Article  PubMed  Google Scholar 

  18. Hiyoshi Y, Yoshida N, Watanabe M, Kurashige J, Baba Y, Sakamoto Y, et al. The presence of serum p53 antibody predicts the pathological tumor response to neoadjuvant chemotherapy with docetaxel, cisplatin and fluorouracil (dcf) in esophageal squamous cell carcinoma. World J Surg. 2017;41:480–6.

    Article  PubMed  Google Scholar 

  19. Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, et al. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol. 2010;17:804–11.

    Article  PubMed  Google Scholar 

  20. Yamamoto K, Makino T, Sato E, Noma T, Urakawa S, Takeoka T, et al. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer. Cancer Sci. 2020;111:1103–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Izadi F, Sharpe BP, Breininger SP, Secrier M, Gibson J, Walker RC, et al. Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. Cancers (Basel). 2021; 13

  22. Booka E, Haneda R, Ishii K, Tsushima T, Yasui H, Tsubosa Y. The negative impact of preoperative chemotherapy on survival after esophagectomy for vulnerable elderly patients with esophageal cancer. Ann Surg Oncol. 2021;28:1786–95.

    Article  PubMed  Google Scholar 

Download references

Funding

No sources of funding were used to assist in the preparation of this article.

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan

    Kotaro Yamashita, Kota Momose, Koji Tanaka, Tomoki Makino, Takuro Saito, Kazuyoshi Yamamoto, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Hidetoshi Eguchi & Yuichiro Doki

Authors
  1. Kotaro Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kota Momose
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomoki Makino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuro Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuyoshi Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tsuyoshi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yukinori Kurokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kiyokazu Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hidetoshi Eguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yuichiro Doki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kotaro Yamashita.

Ethics declarations

Conflict of interest

We have no conflicts of interests to declare in relation to this article.

Ethical approval

This study has a retrospective design and was approved by the Institutional Ethics Review Committee (Certificate No. 08226-10).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamashita, K., Momose, K., Tanaka, K. et al. Indications for neoadjuvant chemotherapy in older patients undergoing esophagectomy for esophageal cancer. Surg Today 54, 442–451 (2024). https://doi.org/10.1007/s00595-023-02752-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-023-02752-3

Keywords

Search

Navigation